Sanofi is in talks with CD&R to sell a 50% stake in its consumer healthcare unit, Opella. PAI Partners raised its bid by 200 ...

In a report released yesterday, Graham Parry from Bank of America Securities maintained a Buy rating on Sanofi (SNYNF – Research Report), ...

PAI Partners has submitted an improved offer for Sanofi’s consumer health business, according to people familiar with the ...

PARIS (Reuters) -French unions have called on workers at Sanofi to strike from Thursday to protest a planned sale of the ...

Sanofi on Friday said it’s in talks with the private equity firm CD&R to sell just over half of its consumer healthcare ...

The French pharmaceutical giant said it’s in negotiations to sell a controlling stake of Opella to the private equity firm CD&R, in a deal that reportedly could be worth more than $16 billion.

Sanofi is entering negotiations with Clayton, Dublier & Rice regarding the potential sale of a 50% controlling stake in its consumer health business, Opella. Sanofi said any further updates on the ...

Sanofi (SNYNF) Company Description: Sanofi engages in the research, production and distribution of pharmaceutical products. It operates through the following business segments: Pharmaceuticals ...

PARIS (Reuters) -Sanofi has entered into talks to sell a controlling 50% stake in its consumer health business Opella to U.S. private equity firm Clayton Dubilier & Rice, the French pharmaceutical ...

On Friday, Sanofi said it’s in negotiations with the private equity firm Clayton Dubilier & Rice for the potential sale of a 50% controlling stake in the consumer business, named Opella.

Sanofi said last week it had entered into talks to sell a controlling 50% stake in its consumer health business Opella to U.S. private equity firm Clayton Dubilier & Rice, a year after flagging ...